GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors.

Journal of Neurochemistry
Catarina A R V GomesJoaquim A Ribeiro

Abstract

Glial cell line-derived neurotrophic factor (GDNF) affords neuroprotection in Parkinson's disease in accordance with its ability to bolster nigrostriatal innervation. We previously found that GDNF facilitates dopamine release in a manner dependent on adenosine A(2A) receptor activation. As motor dysfunction also involves modifications of striatal glutamatergic innervation, we now tested if GDNF and its receptor system, Ret (rearranged during transfection) and GDNF family receptor alpha1 controlled the cortico-striatal glutamatergic pathway in an A(2A) receptor-dependent manner. GDNF (10 ng/mL) enhanced (by approximately 13%) glutamate release from rat striatal nerve endings, an effect potentiated (up to approximately 30%) by the A(2A) receptor agonist CGS 21680 (10 nM) and prevented by the A(2A) receptor antagonist, SCH 58261 (50 nM). Triple immunocytochemical studies revealed that Ret and GDNF family receptor alpha1 were located in 50% of rat striatal glutamatergic terminals (immunopositive for vesicular glutamate transporters-1/2), where they were found to be co-located with A(2A) receptors. Activation of the glutamatergic system upon in vivo electrical stimulation of the rat cortico-striatal input induced striatal Ret phosph...Continue Reading

References

Mar 3, 1994·The New England Journal of Medicine·S A Lipton, P A Rosenberg
Mar 21, 1996·Nature·D M GashG A Gerhardt
Aug 19, 1999·Experimental Brain Research·D S SchatzC Humpel
Sep 29, 1999·Progress in Neurobiology·P SvenningssonB B Fredholm
Sep 11, 2002·Trends in Neurosciences·Michael P Coleman, V Hugh Perry
Jul 31, 2003·The European Journal of Neuroscience·Marzena Karcz-KubichaSergi Ferré
Sep 4, 2003·Journal of Cell Science·Hannu Sariola, Mart Saarma
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Oct 15, 2003·Trends in Molecular Medicine·Jia-Yi LiPatrik Brundin
Dec 31, 2003·Experimental Neurology·Carrie B Hurelbrink, Roger A Barker
Mar 27, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Maria José DiógenesJoaquim Alexandre Ribeiro
Aug 18, 2004·Neurochemistry International·Olimpia PepicelliErnesto Fedele
Nov 16, 2004·Archives of Biochemistry and Biophysics·Zheng FuJonathan M Backer
Dec 31, 2005·Journal of Integrative Neuroscience·Sergi FerréRodrigo Cunha
Feb 17, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Francisco CiruelaRafael Franco
Mar 21, 2006·Lancet Neurology·Roger A Barker
Jun 23, 2006·Neuroscience Letters·Paula A PousinhaAna M Sebastião
Aug 10, 2006·Journal of Neuropathology and Experimental Neurology·Thomas M WishartThomas H Gillingwater
Sep 8, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jelena Mojsilovic-PetrovicRobert G Kalb
Oct 20, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·César QuirozSergi Ferré
Dec 16, 2006·Progress in Neurobiology·Carlos CepedaMichael S Levine
Feb 17, 2007·Progress in Neurobiology·Patrizia PopoliMaria P Abbracchio
Mar 21, 2007·Trends in Neurosciences·Paolo CalabresiMassimiliano Di Filippo
Jul 25, 2007·Progress in Neurobiology·S N SchiffmannS Ferré
Aug 19, 2007·Trends in Neurosciences·Sergi FerréRafael Franco
Oct 18, 2007·Proceedings of the National Academy of Sciences of the United States of America·Stefan WieseMichael Sendtner
May 23, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Catarina C FernandesAna M Sebastião

❮ Previous
Next ❯

Citations

Mar 5, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Clotilde LauroCristina Limatola
Mar 15, 2016·Frontiers in Behavioral Neuroscience·Ahmed M FathallaAhmed A Moustafa
Jul 2, 2014·Frontiers in Psychiatry·Joana E CoelhoLuísa V Lopes
Jul 2, 2010·British Journal of Pharmacology·Sergi FerréSteven R Goldberg
Jul 2, 2016·Journal of Neurochemistry·Rodrigo A Cunha
Jun 11, 2009·British Journal of Pharmacology·Ana M Sebastião, Joaquim A Ribeiro
Dec 15, 2010·Biochimica Et Biophysica Acta·Catarina V GomesRodrigo A Cunha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.